Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

Simple Summary In the fight against cancer, immunotherapies have given great hope after
encouraging results in clinical investigations showing complete remission in some patients …

The recent developments in immuno-oncology have opened an unprecedented avenue for
the emergence of vaccine strategies. Therapeutic DNA cancer vaccines are now considered …

The interaction of the host immune system with tumor cells in the tissue microenvironment is
essential in understanding tumor immunity and development of successful cancer …

The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition
but is commensurate with significant immune-related adverse events suboptimally limiting …

Disabling the function of immune checkpoint molecules can unlock T-cell immunity against
cancer, yet despite remarkable clinical success with monoclonal antibodies (mAb) that block …

Systemic immunotherapies such as immune checkpoint blockade targeted at PD (L) 1 and
CTLA4 have demonstrated their ability to provide durable tumor responses and long-term …

Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer,
remains one of the most challenging problems for the biomedical and clinical fields, with …

Background Recently, cancer immunotherapy has become standard for cancer treatment.
Immunotherapy not only treats primary tumors, but also prevents metastasis and recurrence …

Cancer immunotherapy can successfully promote long-term anticancer immune responses,
although there is still only a limited number of patients who benefit from such treatment, and …